PepGen Inc Stock Price, News & Analysis

PepGen (Nasdaq: PEPG) appointed Joseph Vittiglio, Esq., as Chief Business and Legal Officer effective December 8, 2025. Mr. Vittiglio brings more than two decades of executive leadership in legal, compliance, corporate development, and governance for public biotech companies.

He supported PepGen as a consultant in 2025 and previously led global legal and business functions at bluebird bio, helping support approval and launch of three U.S. gene therapy products and completing $400 million+ in financings. PepGen notes he will help advance the PGN-EDODM1 program ahead of anticipated 2026 readouts from FREEDOM2-EDODM1 5 mg/kg and 10 mg/kg cohorts.

PepGen (Nasdaq: PEPG) announced that the USPTO issued a composition-of-matter patent for its peptide-conjugated oligonucleotide candidate PGN-EDODM1 (Patent No. 12,465,646).

The patent covers PGN-EDODM1 and PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform chemistry, including its unique peptide and linker design, and is expected to provide U.S. exclusivity into the second half of 2042, with potential patent-term extension following FDA approval.

Company leadership described the issuance as a milestone that complements PepGen’s expanding global patent estate and supports the program’s long-term clinical and commercial potential for treating myotonic dystrophy type 1.

PepGen (Nasdaq: PEPG) reported Q3 2025 results and program updates highlighting clinical and financing milestones. The 15 mg/kg cohort of FREEDOM demonstrated a mean splicing correction of 53.7% after a single dose, with all patients improving and adverse events described as mild or moderate. All patients in the FREEDOM2 5 mg/kg cohort are enrolled and dosed; a 5 mg/kg readout is expected in Q1 2026 and 10 mg/kg cohort dosing is planned in Q1 2026 with results targeted in 2H 2026. The company raised $115.0 million in September and held $163.7 million in cash and marketable securities, extending runway into H2 2027. Q3 net loss was $18.0 million (−$0.52/share).

PepGen (Nasdaq: PEPG) announced management will participate in two investor conferences in November 2025: Guggenheim Securities Healthcare Innovation Conference in Boston on November 10, 2025 at 11:30 a.m. ET and a Stifel 2025 Healthcare Conference fireside chat in New York on November 13, 2025 at 4:00 p.m. ET.

A live webcast of each presentation will be available on the Events & Presentations page in the Investors section of PepGen's website at https://investors.pepgen.com/. Replays will remain available on the site for 90 days after each presentation.

PepGen (Nasdaq: PEPG) will present two oral presentations at the 30th Annual International Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-12, 2025. The presentations will feature previously reported data from two clinical trials:

1. Results from the FREEDOM-DM1 Phase 1 study in myotonic dystrophy type 1 patients, focusing on the 15 mg/kg single dose PGN-EDODM1 cohort, presented by Dr. Hanns Lochmüller on October 11th.

2. Dystrophin results from the CONNECT1-EDO51 Phase 2 study of PGN-EDO51 in Duchenne patients amenable to exon 51 skipping, presented by Dr. Hugh McMillan on October 11th.

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company, has successfully closed its previously announced underwritten public offering of 35,937,500 shares of common stock at $3.20 per share, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of $115 million.

The company plans to use the proceeds to fund ongoing research and clinical development initiatives, specifically the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, along with working capital and general corporate purposes. Leerink Partners and Stifel served as joint bookrunning managers for the offering.

PepGen (NASDAQ: PEPG), a clinical-stage biotechnology company, has announced the pricing of a public offering of 31,250,000 shares of common stock at $3.20 per share, aiming to raise $100 million in gross proceeds.

The offering, expected to close around September 26, 2025, includes a 30-day option for underwriters to purchase up to 4,687,500 additional shares. Leerink Partners and Stifel are serving as joint bookrunning managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, along with working capital and general corporate purposes.

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular and neurological diseases, has announced a proposed public offering of common stock and pre-funded warrants.

The offering includes shares of common stock and pre-funded warrants for certain investors, with a 30-day option for underwriters to purchase additional shares. Leerink Partners and Stifel are serving as joint book-running managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and general corporate purposes.

PepGen (Nasdaq: PEPG) announced groundbreaking clinical data from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) treatment. The company's drug candidate PGN-EDODM1 achieved a remarkable 53.7% mean splicing correction at 15 mg/kg dosing - the highest ever reported in DM1 patients.

The trial demonstrated 100% patient response rate with improved splicing correction. Safety data showed the treatment was generally well-tolerated, with only mild or moderate adverse events. The company previously reported 12.3% and 29.1% splicing correction at 5 mg/kg and 10 mg/kg doses respectively, showing greater than dose-proportional increases.

PepGen plans to report results from its multiple ascending dose (MAD) study's first cohort in Q1 2026.